Dataset Information
Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.
Ontology highlight
ABSTRACT:
SUBMITTER: Liu A
PROVIDER: S-EPMC12911015 | biostudies-literature | 2026 Jan
REPOSITORIES: biostudies-literature
Publications
Esketamine alleviates COPD-depression comorbidity in rats via MAPK/NF-κB inhibition and gut-lung-brain axis modulation.
Journal of neuroinflammation 20260122 1
BACKGROUND: Chronic obstructive pulmonary disease (COPD) and depression frequently co-occur, yet the biological basis of this comorbidity and effective therapeutic strategies remain poorly defined. METHODS: We established a rat model of COPD-depression comorbidity through sequential cigarette-smoke exposure and chronic unpredictable mild stress. Pulmonary function, depression-like behaviors, histopathology, and MAPK/NF-κB signaling in lung and hippocampus were assessed. Esketamine or esketamine ...[more]